{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:10:52Z","timestamp":1771409452835,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":128,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without single-photon emission computed tomography (SPECT) in patients with hypertrophic cardiomyopathy (HCM) screened for ATTR-CM in the TTRACK study. Variability in readings based on different readers, tests and radiotracers used in cardiac nuclear imaging, and differences in echocardiogram findings between patients with and without ATTR-CM were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged \u226550 years with HCM (left-ventricular wall thickness \u226515 mm without an identified cause) underwent diagnostic technetium-99m [99mTc]Tc-DPD [3,3-diphosphono-1,2-propanodicarboxylic acid], -PYP [pyrophosphate] and -HMDP [hydroxymethylene diphosphonate]\u2013labelled planar bone scintigraphy with or without SPECT. Cardiac-versus-bone uptake on images was visually graded (Perugini, 0\u20133) by onsite and central readers (discrepancies resolved by consensus). Patients with grade 1\u20133 cardiac uptake underwent monoclonal protein testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 766 eligible patients (mean age \u00b1 standard deviation, 72.3 \u00b1 10.6 years, 69.6% male), 691 (90.2%) had planar imaging alone and 75 (9.8%) planar plus SPECT imaging. Cardiac uptake was observed on imaging in 245 patients (32.0%); grades 1, 2 and 3 were assigned in 37 (4.8%), 34 (4.4%) and 174 (22.7%), respectively. Initial cardiac uptake grading for planar scintigraphy by onsite readers was strongly concordant with consensus decisions [\u03ba coefficient, 0.84 (95% confidence interval 0.81\u20130.88)]. Grading for planar versus SPECT imaging was very strongly concordant [0.93 (95% confidence interval 0.86\u20131.00)]; discordant findings were only observed with [99mTc]Tc-PYP. Compared with patients with no cardiac uptake, patients with ATTR-CM had a lower mean left ventricular (LV) ejection fraction (55.7% vs. 61.4%; P &amp;lt; 0.001), higher mean LV mass index (179.0 vs. 155.6 g\/m2; P &amp;lt; 0.01), a higher rate of preserved apical strain (73.4% vs. 57.9%; P &amp;lt; 0.05) and differences in hypertrophic pattern (P &amp;lt; 0.001), such as a higher rate of concentric hypertrophic pattern (77.5% vs. 38.8%;). Clinical overlap between patients with ATTR-CM and those without cardiac uptake was high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world study, a high level of concordance was seen in cardiac uptake grading on planar versus SPECT imaging, with discordant findings only observed with [99mTc]Tc-PYP. The findings support the use of these imaging tools to facilitate ATTR-CM screening in clinical practice. Further studies should investigate differences across tracers used in ATTR-CM screening. NCT03842163.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15440","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:54:04Z","timestamp":1760406844000},"page":"4349-4358","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuclear Imaging and Echocardiographic Findings in Hypertrophic Cardiomyopathy with and without ATTR-CM"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"first","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV , Majadahonda ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]},{"name":"Universidad Francisco de Vitoria (UFV) , Pozuelo de Alarcon ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier Haro","family":"del Moral","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV , Majadahonda ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1622-0732","authenticated-orcid":false,"given":"Francesco","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Piriou","sequence":"additional","affiliation":[{"name":"L'institut du Thorax and Nuclear Medicine Department, CHU Nantes, Nantes Universit\u00e9 , Nantes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[{"name":"Complexo Hospitalario Universitario A Coru\u00f1a, INIBIC, CIBERCV , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Munteanu","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Bahus","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Keohane","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Mallaina","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires Henri-Mondor AP-HP, and IMRB, INSERM, Universit\u00e9 Paris Est Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires Henri-Mondor AP-HP, and IMRB, INSERM, Universit\u00e9 Paris Est Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[{"name":"University College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2026021804193558600_ehf215440-bib-0001","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0002","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/circulationaha.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026021804193558600_ehf215440-bib-0003","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804193558600_ehf215440-bib-0004","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021804193558600_ehf215440-bib-0005","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021804193558600_ehf215440-bib-0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2024.07.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","author":"Garc\u00eda-Pav\u00eda","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026021804193558600_ehf215440-bib-0007","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021804193558600_ehf215440-bib-0008","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/circulationaha.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026021804193558600_ehf215440-bib-0009","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0010","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026021804193558600_ehf215440-bib-0011","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0012","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"key":"2026021804193558600_ehf215440-bib-0013","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-10-S1-P22","article-title":"Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium","volume":"10","author":"Lousada","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"2026021804193558600_ehf215440-bib-0014","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.cardfail.2019.07.197","article-title":"Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL and ATTR amyloidosis and their caregivers","volume":"25","author":"Lousada","year":"2019","journal-title":"J Card Fail"},{"key":"2026021804193558600_ehf215440-bib-0015","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026021804193558600_ehf215440-bib-0016","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021804193558600_ehf215440-bib-0017","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0018","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0019","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221082","article-title":"99mTc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis","volume":"306","author":"Khor","year":"2023","journal-title":"Radiology"},{"key":"2026021804193558600_ehf215440-bib-0020","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804193558600_ehf215440-bib-0021","doi-asserted-by":"publisher","DOI":"10.1161\/hci.0000000000000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026021804193558600_ehf215440-bib-0022","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0023","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026021804193558600_ehf215440-bib-0024","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804193558600_ehf215440-bib-0025","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0026","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021804193558600_ehf215440-bib-0027","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021804193558600_ehf215440-bib-0028","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0029","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804193558600_ehf215440-bib-0030","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/circimaging.112.000132","article-title":"99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026021804193558600_ehf215440-bib-0031","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","author":"Galat","year":"2015","journal-title":"Amyloid"},{"key":"2026021804193558600_ehf215440-bib-0032","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s12350-017-0922-z","article-title":"Accuracy of 99mTc-hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis","volume":"26","author":"Cappelli","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026021804193558600_ehf215440-bib-0033","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-023-01054-x","article-title":"Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis","volume":"23","author":"Park","year":"2023","journal-title":"BMC Med Imaging"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4349\/66968395\/eschf_12_6_4349.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4349\/66968395\/eschf_12_6_4349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:19:43Z","timestamp":1771406383000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4349\/8488193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,13]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15440","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"2025-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}